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Urokinase type plasminogen activator
Plasminogen activator inhibitor-1Urokinase type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) have
been proposed to play key roles in extracellular matrix (ECM) deposition in hypertrophic scars
(HS). Here, we found that in HS ﬁbroblasts (HFs) miR-181c and miR-10a were differentially-
expressed and targeted uPA and PAI-1, respectively. The production of Type 1 collagen (Col1) was
inhibited by miR-181c knockdown or miR-10a overexpression in HFs, and this resulted in increased
levels of metalloproteinase 1 (MMP1). These results suggest that the miR-181c–uPA and miR-10a–
PAI-1 regulatory pathways have an integral role in HS pathogenesis.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hypertrophic scarring (HS), a ﬁbroproliferative and abnormal
wound healing process after skin injury, is characterized by an
excessive dermal deposition of type 1 collagen (Col1), the main
structural element of the extracellular matrix (ECM). The ECM
forms a ﬁrm network of cross-linked long-chain ﬁbers to give
integrity to the scar [1–3]. In normal skin, the synthesis and degra-
dation of ECM is controlled by numerous cytokines, but the imbal-
ance between these pro- and anti-ﬁbrosis related cytokines during
the remodeling phase of wound healing might lead to HS.
Recently, the role of urokinase-type plasminogen activator
(uPA) and plasminogen activator inhibitor-1 (PAI-1) in the regula-tion of ECM degradation has been proposed in many studies, most
of which are related to ﬁbrotic diseases [4], especially skin ﬁbrosis,
such as sclerosis and keloids. uPA and PAI-1 were reported to be
involved in breast cancer metastasis via degradation of basilar
membrane [5,6], but their function in breast cancer was likely an
interaction with the ECM microenvironment and collagen metabo-
lism. PAI-1, a member of the serpin family, is a main inhibitor for
both urokinase-type and tissue-type plasminogen activators (uPA
and tPA). The functions of uPA and PAI-1 in the regulation of
ECM generation are opposite: uPA induces degradation of ECM
[7,8], but PAI-1 exerts pro-ﬁbrotic functions through inhibition of
uPA [9]. Matrix metalloproteinases1 (MMP1) is believed to break-
down ECM, especially Col1 [10]. uPA positively regulates MMP1,
but PAI-1 negatively regulates MMP1 [11]. Thus, a physiologic bal-
ance of uPA and PAI-1 is essential to maintain ECM proteins and
tissue homeostasis [4,12]. The pro-ﬁbrogenic function of PAI-1 in
skin ﬁbrosis, such as keloid and sclerosis has been documented
[13,14]. However, the role of PAI-1 in HS remains unclear. There-
fore, we hypothesize that an imbalance between PAI-1 and uPA,
caused by dysregulation of their expression during the remodeling
phase of wound healing, may lead to abnormal scarring and cause
HS.
MicroRNAs (miRNAs) are non-coding small RNA molecules
capable of silencing gene expression by inducing degradation or
C. Li et al. / FEBS Letters 589 (2015) 380–389 381translational repression of target gene mRNAs, via a manner of
binding complementary sequences in 30-untranslated regions (30-
UTR) of miRNA-targeted genes [15,16]. In recent years, the roles
of miRNAs in tissue ﬁbrosis, such as cell growth, proliferation,
ECM deposition, and collagen degradation has been recently
reported [17,18]. To date, increasing bodies of miRNAs have been
found to be dysregulated in ﬁbrotic tissues, but only a fraction of
differentially expressed miRNAs in ﬁbrotic diseases has been func-
tionally characterized [19]. Since the regulation of PAI-1 and uPA
by differentially expressed miRNAs in HS has not been well docu-
mented, in this study, we identify differentially expressed miRNAs
in HS tissues and investigated the correlation of the dysregulated
miRNAs and the imbalance between PAI-1 and uPA.
Our study revealed the aberrant expression of uPA and PAI-1 at
both mRNA and protein levels in hypertrophic scar-derived ﬁbro-
blasts (HFs), as compared to that of normal skin-derived ﬁbroblasts
(NFs). Our study also revealed that differentially expressed miRNAs
in HS are associatedwith dysregulated expression of uPA and PAI-1.
2. Material and methods
2.1. Tissue samples and cell culture
Hypertrophic scar and paired normal skin tissues were surgi-
cally obtained from sixteen Chinese patients (Table 1). Diagnosis
of HS was conﬁrmed by routine pathological examination. All
experiments were conducted with approval of the ethics commit-
tee of the Xijing Hospital and in accordance with the Declaration of
Helsinki Principles.
Primary culture of dermal ﬁbroblasts was established as
described previously [20]. Fibroblasts used in this study were
obtained from the primary culture (passage 0), unless otherwise
indicated.
2.2. Real-time quantitative RT-PCR
First, total RNA was extracted using TRIzol Reagent (Invitrogen,
CA, U.S.), according to the manufacturer’s instructions. Total RNA
was then used as template for mRNA reverse-transcription, using
a High-capacity RNA-to-cDNA Kit (Applied Biosystems). For
quantifying miRNAs, a miScript reverse transcription kit (Qiagen,
Hilden, Germany) was used for reverse transcription, followed by
ampliﬁcation using SYBR@Premix ExTaq™ (TaKaRa, Shiga, Japan).Table 1
The proﬁle of each sample for primary culture.
HFs and NFs from 16 patients Sex Age (years) Biopsy site Dura
Cell types
HF/NF 1a Male 21 Shoulder 6
HF/NF 2 Female 16 Chest 8
HF/NF 3 Female 27 Arm 13
HF/NF 4 Female 43 Shoulder 11
HF/NF 5 Male 38 Chest 17
HF/NF 6 Female 24 Shoulder 9
HF/NF 7 Male 36 Buttock 7
HF/NF 8 Male 12 Cheek 10
HF/NF 9 Male 21 Shoulder 5
HF/NF 10 Female 16 Chest 14
HF/NF 11 Female 27 Cheek 12
HF/NF 12 Female 43 Back 8
HF/NF 13 Male 38 Chest 17
HF/NF 14 Male 24 Shoulder 24
HF/NF 15 Female 44 Back 20
HF/NF 16 Male 19 Arm 15
Abbreviations: HF, hypertrophic scar derived ﬁbroblast; NF, normal skin ﬁbroblast; ope,
a The indicated person derived samples were used for Affymetrix miRNA microarray.
b Both: treatment methods included Topi cal silicon gel and Pressure garment.qRT-PCR for analysis of the expression levels of miRNA and mRNA
was conducted using a Bio-Rad C1000 Thermal Cycler (Bio-Rad)
and triplicate reactions were included. GAPDH and RNU6B RNA
were used as internalloading controls for mRNAs and miRNAs,
respectively. The following primers were used for the ampliﬁcation
of miRNAs by qRT-PCR: universal primer (UP) included in the
miScript reverse transcription kit (Qiagen) and 50-TAC-
CCTGTAGATCCGAATTTGTG-30; 50-AACATTCAACCTGTCGGTGAGT-
30; 50-ACGCAAATTCGTGAAGCGTT-30 for miR-10a; miR-181c;
RNU6B RNA (AUGCT, Beijing, China), respectively. Primers used
in PCR for mRNA quantiﬁcation are listed in Table 2.
2.3. Construction of the expression vector and siRNA
A DNA fragment containing the sequence of the PAI-1 open
reading frame region was ligated into the pENTR vector (YouBio,
Changsha, China) to make pENTR-PAI-1-orf and then this gene
fragment was transferred into the destination vector,
pcDNA™3.2-DEST (Invitrogen, U.S.). The siRNA used in our study
was designed as a 19 bp RNA duplex that is complementary to
the sequence of uPA mRNA. To establish an shRNA vector, paired
deoxyribonucleotide oligonucleotides encoding uPA siRNA were
synthesized, annealed, and cloned into the pSUPER vector
(GenePharma, Shanghai, China). Stable transfection of uPA siRNA
was performed according to standard protocols as recommended
by the manufacturers and the empty vector was used as a control.
2.4. Luciferase reporter assay
The 30untranslated region (UTR) fragments of uPA and PAI-1
containing the miRNA binding sites were ampliﬁed by PCR using
the cDNA template obtained from RNA sample of HFs. The wide-
type 30UTRs of uPA and PAI-1 as well as mutant 30UTRs with nucle-
otide substitutions in the putative binding sites corresponding to
the seed sequence of miR-181c and miR-10a were cloned down-
stream of the ﬁreﬂy luciferase gene in the pGL3 vector (Promega,
Madison, WI). The reporter construct of uPA-30UTRs was co-trans-
fected with miR-181c or a control miRNA into HEK293T cells. Sim-
ilarly, the PAI-1-30UTRs reporter was also co-transfected with miR-
10a or a control miRNA into HEK293T cells. 48 h after transfection,
cells were rinsed in PBS and their luciferase activity was measured
by a luminometer (Promega), using dual luciferase reporter assay
system.tion of the lesion (months) Etiology Previous treatment
Burn Bothb
Trauma Topi cal silicon gel




Burn Topical silicon gel
After ope. Topical silicon gel
Scald Bothb
Scald Topical silicon gel
Burn Pressure garment
Trauma _
After ope. Resection and electron beam
Scald Pressure garment
Scald Topical silicon gel
Electric injury Topical silicon gel
operation.
Table 2
The primers used in Real-time PCR.
Primer Sequence (50 ? 30)
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Western blotting was performed as previously described [19],
using an anti-uPA rabbit monoclonal antibody (ab169754, 1:1000
dilution, Abcam, U.S.), anti-PAI-1 mouse monoclonal antibody
(ab125687, 1:1000 dilution, Abcam, U.S.) and anti-beta-actin
mouse monoclonal antibody (ab133626, 1:2000 dilution, Abcam,
U.S.). Signals were recorded using an Odyssey Infrared Imaging
System (LI-COR Biosciences, NE, U.S.).
2.6. Immunoﬂuorescence of tissue samples
Skin tissues were ﬁxed in 4% paraformaldehyde. For immuno-
ﬂuorescence analysis, the sections were ﬁrst blocked with 1%
bovine serum albumin and then incubated with both polyclonal
antibody against uPA (ab24122, 1:1000, Abcam, U.S.) and PAI-1
(ab66705, 1:1000, Abcam, U.S.), washed and incubated with sec-
ondary antibodies: both Cy3 Donkey Anti-Goat IgG (cw0216,
1:500, CW Biotech) and FITC Goat Anti-Rabbit IgG (cw0114, 1:50,
CW Biotech). Finally, the sections were mounted using VectashieldFig. 1. Expression of uPA and PAI-1, miR-181c and miR-10a in hypertrophic scar-der
expression of uPA and PAI-1 between HFs and NFs (passage 0) using 16 paired tissue samp
NFs (passage 0–2), using 16 paired tissue samples. b-actin was used as a loading control. (
Bars represent the mean ± S.D. (⁄P < 0.05, ⁄⁄P < 0.01).with DAPI (BD5010, 2 lg/ml, Bioworld) and ﬂuorescence was
observed with microscopy (FV10i, Olympus).
2.7. ELISA for detection of collagen type 1 (Col1) and MMP1 levels
The culture medium was replaced with conditioned medium
containing AA-2P (Sigma, U.S.), at the sixth hour after transfection.
Then every 24 h, the medium was changed. The collected medium
was used to detect the concentration of total MMP1 and collagen
type I triple helix by humanMMP-1 (Merck, Japan) and human col-
lagen type I (ACEL, Japan) enzyme-linked immunosorbent assay
(ELISA) kits, respectively.
2.8. Statistical analysis
All experiments were performed in triplicate and all data are
presented as mean ± standard deviation (S.D.). Two-tailed
unpaired Student’s t-test (except where otherwise stated) was
used for statistical analysis. P values < 0.05 were considered statis-
tically signiﬁcant and are indicated with a single asterisk (⁄). In
addition, P values < 0.01 are indicated with a double asterisk (⁄⁄)
and P values < 0.001 are indicated with a triple asterisk (⁄⁄⁄).3. Results
3.1. Aberrant expression of uPA and PAI-1 in HFs
To compare the expression levels of uPA and PAI-1 between HFs
and NFs, 16 pairs of tissue samples from HS and normal skin wereived ﬁbroblasts (HFs) and normal ﬁbroblasts (NFs). (A, B) Comparison of mRNA
les. (C) Western-blot analysis for the protein expression of uPA and PAI-1 in HFs and
D, E) Validation of miR-181c and miR-10a expression in HFs and NFs using qRT-PCR.
Fig. 2. Correlations between miR-181c expression and uPA level as well as miR-10a and PAI-1. (A) An inverse correlation of miR-181c expression with uPA level was found in
HS tissue samples. (B) An inverse correlation of miR-10a and PAI-1 was found in HS tissue samples. (C, D) Examination of uPA and PAI-1 expression in HS tissue samples (C:
case #5 and D: case #9) by immunoﬂuorescence staining: uPA-positive (red) and PAI-1-positive (green).
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expression of uPA was decreased in HFs, as compared to that of
NFs at mRNA and protein levels (Fig. 1A and C). In contrast, an ele-
vated PAI-1 expression was found in cultured HFs (Fig. 1B and C)
compared to NFs.
3.2. Aberrant expression of miR-181c and miR-10a in HFs
To validate miRNA microarray data (Fig. S4) and the prediction
of TargetScan, the expression of miRNAs in 16-paired ﬁbroblasts
was examined by qRT-PCR assay (Table 1). As compared to NFs,
overexpression of miR-181c was found in HFs (Fig. 1D). On the
other hand, downregulation of miR-10a was also detected in HFs
(Fig. 1E).
3.3. Correlation of altered miRNAs and aberrant expression of uPA and
PAI-1 in HFs
To evaluate the correlation of miR-181c or miR-10a with uPA
and PAI-1 in HS, their expression was examined in 16 tissue sam-
ples of HS by qRT-PCR. As shown in Fig. 3A and B, a negative cor-
relation was found between level of endogenous miR-181c and
uPA mRNA, and between miR-10a and PAI-1.
Immunoﬂuorescence staining also conﬁrmed the conclusion
drawn from PCR data of HS tissues and NS tissues (Fig. 2A–D and
S.2F). Among all HS tissues, case #5 (Fig. 2C) was characteristic
of a relatively high level of miR-181c, but low level of miR-10a.
Another case (#9) (Fig. 2D) showed a relatively low level ofmiR-181c, but a high level of miR-10a. Compared to #9, the ﬂuo-
rescence signals of PAI-1 proteins with a positive immunostaining
were much higher in #5; however, the signals of immunostained
uPA proteins were much less.
3.4. Identiﬁcation of uPA and PAI-1 genes as direct targets of miR-181c
and miR-10a
The high conservation, across different species, of the putative
binding sites of miR-181c or miR-10a in the region of 30-UTR of
uPA or PAI-1, respectively, was found by bioinformatics analysis
(Figs. 3A and 4A). To verify the binding sites, the region containing
the wild type or the mutated seed-sequence of miR-181c or miR-
10a in the 30UTR of uPA or PAI-1, respectively, was cloned into
the luciferase reporter plasmids (Figs. 3B and 4B). A dual luciferase
reporter gene assay showed that in the presence of miR-181c or
miR-10a, the luciferase activity of the wild-type reporter in the
transfected HEK-293T cells was inhibited, but those miRNA-medi-
ated inhibitory effects were not observed in the mutant reporter-
transfected cells (Figs. 3C and 4C). These results indicate that
uPA or PAI-1 is a direct target gene of miR-181c or miR-10a,
respectively.
To verify the role of miR-181c or miR-10a in regulating uPA or
PAI-1 expression, respectively, qRT-PCR and Western blot assays
were performed using the samples from both HFs and NFs. Because
of the relatively higher level of miR-181c and lower level of miR-
10a in HFs as compared to NFs, we transfected miR-181c mimics
and miR-10a inhibitors into NFs. In contrast, the miR-181c inhibi-
Fig. 3. Identiﬁcation of uPA as a target of miR-181c. (A) Putative binding site of miR-181c within the 30UTR of uPA. The binding site sequences are highly conserved across
different species. (B) According to the sequence of the miR-181c binding site within the 30UTR of human uPA, the luciferase reporter with either wild-type or mutant
sequences of uPA 30UTR was constructed, using pGL3 vectors. (C) 48 h after transfection, relative luciferase activity in HEK-293T cells was measured. The data represents
ﬁreﬂy luciferase activity units (relative light units, RLU) from three separate experiments. RLU were normalized to renilla luciferase activity. (D) NFs were transfected with
miR-181c mimic and mimic control (mimic-ctrl), and HFs were transfected with miR-181c inhibitor and inhibitor control (inhibitor-ctrl). The miR-181c levels in the
transfected cells were examined by qRT-PCR analysis. (E) At 48 h after transfection, qRT-PCR and (F) Western-blot analyses were used to evaluate the expression level of uPA
in NFs (+miR-181c mimic) and HFs (+miR-181c inhibitor). All values are normalized to either the mimic control (mimic-ctrl) or inhibitor control (inhibitor-ctrl).
384 C. Li et al. / FEBS Letters 589 (2015) 380–389tors and miR-10a mimics were transfected into HFs. Results
showed that the mRNA and protein levels of uPA or PAI-1 were
decreased in the cells transfected with either miR-181c mimics
or miR-10a mimics, as compared with their levels in the control
groups (Figs. 3D–F and 4D–F). These results suggest that miR-
181c and miR-10a may regulate the gene expression of uPA and
PAI-1, respectively, at both the mRNA and protein levels.
3.5. Altered miRNAs in HFs signiﬁcantly impact production of type I
collagens and MMP1
In our study, collagen type I as the most abundant collagen
within the abnormal ECM deposits in HS [1–3,10,21], was selectedto evaluate the role of miR-181c and miR-10a in the regulation of
ECM degradation. As uPA and PAI-1 are well-known cytokines
implicated in ECM degradation and their expression is regulated
by miRNAs, we examined whether miRNAs treatment could reduce
Col1 expression in HFs and NFs cells. Through the transfection of
miR-181c inhibitor and miR-10a mimic, a reduced Col1 expression
in HFs (Fig. 5A–B), but not in NFs (S.1A–D), was detected by ELISA.
Furthermore, co-transfection of miR-10a mimics and miR-181c
inhibitors together in HFs was still decreased the expression of
Col1 (S.2A–E).
The MMP1 expression levels in HFs transfected with either miR-
181c inhibitors or miR-10a mimics were determined by ELISA. As
shown in Fig. 5C–D, both miR-181c inhibitors and miR-10a mimics
Fig. 4. Identiﬁcation of PAI-1 as a target of miR-10a. (A) Putative binding site of miR-10a within the 30UTR of PAI-1. The binding site sequences are highly conserved across
different species. (B) According to the sequence of the miR-10a binding site within the 30UTR of human PAI-1, the luciferase reporter with either wild-type or mutant
sequences of PAI-1 30UTR was constructed, using pGL3 vectors. (C) 48 h after transfection, the relative light units (RLU) of HEK-293T cells were examined and normalized to
renilla luciferase activity. To conﬁrm that miR-10a speciﬁcally binds to PAI-1 30UTR, the luciferase activities of pGL3-PAI-1-wt and pGL3-PAI-1-mut in the presence of miR-
10a mimic were determined and compared to the RLU of cells transfected with mimic-ctrl. (D) HFs were transfected with miR-10a mimic and mimic control (mimic-ctrl), and
NFs were transfected with miR-10a inhibitor and inhibitor control (inhibitor-ctrl). miR-10a expression levels in transfected cells were evaluated by qRT-PCR. (E) At 48 h after
transfection, qRT-PCR and (F) Western-blot analyses were used to evaluate the expression level of PAI-1 in HFs (+miR-10a mimic) and NFs (+miR-10a inhibitor). All values are
normalized to either the mimic control (mimic-ctrl) or inhibitor control (inhibitor-ctrl).
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signiﬁcant change in MMP1 expression in the transfected NFs
(S.3A–D).
3.6. The decreased expression of Col1 could be rescued by uPA
inhibition or PAI-1 overexpression in HFs
As shown in Fig. 6A and B, the up-regulated mRNA and protein
expression of uPA induced by miR-181c-inhibitors could be signif-
icantly inhibited by siRNA-uPA transfection, leading to a decreased
MMP1 and increased Col1 production (Fig. 6C and D). Since PAI-1
expression was down-regulated in HFs by transfection of miR-
10a mimics (Fig. 6E and F), our study showed that reintroduction
of PAI-1 using a eukaryotic expression vector, signiﬁcantly restored
the level of PAI-1 in those cells and induced a signiﬁcant decrease
in MMP1 and increase in Col1 levels in the culture media (Fig. 6G
and H).4. Discussion
Collagen metabolism disorder after skin damage is the major
pathogenesis in the production of HS [22]. PAI-1 expression has
been shown to be remarkably increased in the process of wound
healing [23,24], which may accelerate wound repair. However,
the persistent overexpression of PAI-1 will cause collagen metabo-
lism impairment, promoting collagen deposition and leading to
various organ ﬁbrosis. The role of cytokines, especially PAI-1, in
the pathogenesis of keloid scars has been reported [25]. Mean-
while, the differential expression of uPA and PAI-1 was found at
the edge of wounds in mice [26]. The changes in the expression
of those genes may be involved in the migration of keratinocytes
and connective tissue cells during re-epithelialization and tissue
remodeling in wound healing. However, the wounded mouse is
not capable of developing HS at the end stage of wound healing.
In addition, HS can only happen after the wound is closed [20].
Fig. 5. Effect of miR-181c and miR-10a on Col1 and MMP1 expression in HFs. At 48 h after transfection of miR-181c inhibitors, (A) the decreased amount of collagen type I
(Col1) and (C) increased amount of MMP1 was detected in the supernatant of cultured HFs as compared to inhibitor-ctrl. (B) Transfection of miR-10a mimics signiﬁcantly
inhibited Col1 expression at 48 and 72 h after transfection. (D) In contrast, the amount of MMP1 was increased after transfection of miR-10a mimics, as compared to mimic-
ctrl. The concentration of Col1 and MMP1 in conditioned medium was measured by ELISA every 24 h after transfection. Bars represent the mean ± S.D. (⁄P < 0.05, ⁄⁄P < 0.01,
n = 3).
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wound healing or HS, the changes in the expression of those genes
may be involved in different biological and pathological processes.
Therefore, our ﬁndings might have novelty that will lead to a better
understanding of the development of HS. In our study, we investi-
gated and found that PAI-1 expression was up-regulated in the pri-
mary ﬁbroblasts isolated from HS, as compared to that in NFs.
Furthermore, we also revealed that re-introduction of PAI-1 into
HFs indeed increased the expression of Col1, accompanied with
decreased MMP1, which is consistent with previous reports about
the role of PAI-1 in collagen synthesis of keloid [23,27]. It is antic-
ipated that an increased PAI-1 expression in HFs could be one of
the causes that contributes to the pathogenesis of HS, which might
be considered a promising target for the treatment of skin ﬁbrosis.
uPA, a target molecule of PAI-1, was previously reported to be
involved in the protein degradation of the basement membrane;
up-regulated uPA expression causes ECM degradation of tissues
surrounding tumors, thereby promoting tumor metastasis [6].
Although little is known about the anti-ﬁbrosis function of uPA,
some studies revealed that overexpression of uPA is involved in
collagen degradation, alleviating liver ﬁbrosis [28], and that uPA
can accelerate the invasion of retinal pigment epithelial cells
through collagen gels [29]. In terms of idiopathic pulmonary ﬁbro-
sis, Gharaee-Kermani et al. suggested that an approach to target
uPA may be a promising new therapeutic strategy [30]. On the
other hand, the pro-ﬁbrosis function of uPA was found in cardiac
ﬁbrosis, for example, macrophage-derived uPA increases collagen
level following myocardial ischemia [31]. The above informationindicates that either the pro-ﬁbrosis or anti-ﬁbrosis functions of
uPA depend on tissue speciﬁcity. In our study, we found decreased
expression of uPA in HFs, as compared to that in NFs. Moreover, we
revealed that the anti-ﬁbrosis function of uPA is predominant in
HS, because transfection of HFs with siRNA-uPA can promote the
production of Col1, accompanied with decreased MMP1, implicat-
ing that a decreased uPA expression in HFs may be associated with
the pathogenesis of HS.
Aberrant expression of miRNAs is involved in wound healing
and underlying mechanisms are related to posttranscriptional reg-
ulation of the miRNA-targeting gene expression [32,33]. Therefore,
targeting a speciﬁc mRNA that is aberrantly expressed and linked
to a particular disease may offer clinicians new therapeutic options
[34]. Our study showed that either miR-181c or miR-10a was dif-
ferentially expressed in HFs, as compared to the paired NFs derived
from the same person. Meanwhile, we also found that up-regulated
miR-181c or down-regulated miR-10a expression in HFs was
inversely correlated with the level of uPA or PAI-1, respectively.
The relationships between miR-181c and uPA as well as miR-10a
and PAI-1 were examined by computational analysis and luciferase
reporter assay using reporter plasmids containing wild-type or
mutant 30-UTR of uPA and PAI-1. In addition, the methods for over-
expression or inhibition of these two miRNAs in HFs or NFs were
also used to verify the computational prediction and results of
reporter assay. All of our results supported our hypothesis that
uPA and PAI-1 genes are direct targets of miR-181c and miR-10a,
and those two target genes are regulated by differentially
expressed miR-181c and miR-10a in HS.
Fig. 6. Inhibition of uPA or overexpression of PAI attenuated the effect of miRNAs (miR-181c or miR-10a) on Col1 expression. siRNA-uPA transfection restored the expression
level of uPA mRNA (A) and protein (B), which had been upregulated by miR-181c inhibitors. (C) siRNA-uPA transfection restored the level of MMP1 in HFs, which had been
up-regulated by miR-181c inhibitors. (D) siRNA-uPA transfection also restored the level of Col1 in HFs, which had been reduced by miR-181c inhibitors. Transfection of
pcDNA-PAI-1-orf restored PAI-1 mRNA (E) and protein (F) expression that had been suppressed by miR-10a mimic. (G) Overexpression of PAI-1 in HFs transfected with miR-
10a mimic rescued the increased MMP1 expression induced by miR-10a mimics. (H) Overexpression of PAI-1 in HFs transfected with miR-10a mimic restored the decreased
level of Col1 caused by miR-10a mimics. The concentration of MMP1 and Col1in conditioned medium was measured by ELISA at 48 h after transfection. Bars represent the
mean ± S.D. (⁄P < 0.05, ⁄⁄P < 0.01, n = 3).
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metastasis [35]. On the other hand, the inhibition of miR-181c
expression could increase cell migration, and invasion in neuroblas-
toma cells [36], whereas overexpression of miR-10a enhanced the
metastatic potential of many cancer cells [37,38]. These resultssupport our ﬁndings that miR-181c inhibition andmiR-10a overex-
pression may downregulate Col1 production. It was previously
reported that Col1 production was induced by overexpression of
PAI-1 [27]. Similarly, we found that ectopic expression of miR-10a
could inhibit PAI-1 expression and up-regulate MMP1 expression,
388 C. Li et al. / FEBS Letters 589 (2015) 380–389thereby reducing the production of Col1 in HFs. miR-181c inhibi-
tion led to up-regulation of uPA and MMP1 expression in HFs,
resulting in a decrease in Col1 production. Although Col1 produc-
tion was decreased by only 20% in miR-181c inhibitors-treated
HFs, it is acceptable because the effect of miR-181c inhibitors on
uPA expression might be limited and ECM degradation involves
multiple targets of uPA, except for Col1. In contrast, although
miR-181c mimics can decrease uPA expression and miR-10a inhib-
itors can induce PAI-1 expression in NFs, those changes did not
show much effect on Col1 production (S2.A-D). Moreover, MMP1
as the Col1 regulatory protease was also not affected by the trans-
fection of miRNAs mimics and inhibitors. It seems that the expres-
sion of MMP1 cannot be regulated by miR-181c or miR-10a under
normal conditions. These contradictory results between HFs and
NFs are not unique in our experiments; the phenomenon was also
observed in a study reported by Aoki et al. [39]. In their study,
knockdown of the tissue inhibitor ofMMP1 in NFs using siRNA did
not lead to degradation of Col1 or decreased cell viability, as com-
pared to the efﬁcacy of the same siRNA in keloid ﬁbroblasts. These
ﬁndings indicated that there might be a crucial difference between
HFs and NFs, and it may implicate that these altered expression of
PAI-1 or uPA has less effect on skin ﬁbroblasts under normal
condition.
In terms of gene therapy, miRNAs have the potential to treat
ﬁbrotic diseases by taking advantage of small molecules and neg-
ative regulation of speciﬁc target genes. Recently, several miRNAs
were found to be involved in pro-ﬁbrogenic pathways [40,41].
Previous studies also revealed that miR-29 family members and
miR-101 exert their anti-ﬁbrotic functions through the inhibition
of the transforming growth factor-b (TGF-b) pathway [42,43],
which is usually thought to be a pro-ﬁbrotic pathway [44]. We
found that up-regulated miR-181c inhibited uPA expression in
HS tissues. Our ﬁndings are consistent with other study, in which
miR-181c was also found to inhibit Smad7 expression in neuro-
blastoma cells [36]. These results suggest that miR-181c may
exert its pro-ﬁbrotic functions through activation of TGFb/Smad
pathway, because smad7 plays a suppressive role in the TGF-b
pathway. Collectively, all of these data indicate that the regulation
of miRNA expression by manipulating the intracellular levels of
speciﬁc miRNA could be a potential treatment strategy for HS.
Although a smaller sample size in this study is acceptable, it is
necessary to increase the number of patients enrolled in our
future studies [40]. In addition, as to the enhanced secretion of
total MMP1 within HFs after treatment, it is unknown whether
it this resulted from a functional change or aberrant behavior;
therefore, this needs to be further clariﬁed. Finally, to test our
hypothesis about the roles of two miRNAs in HS, the therapeutic
effects of miR-181c inhibitor and miR-10a mimic on scar reduc-
tion were investigated through in vitro assays using cultured
HFs. However, in future studies, methods using either HS organ
culture or an HS animal model should be considered [45].
In summary, the correlation between differentially expressed
miRNAs and the aberrant expression of genes related to the pro-
duction of pro-ﬁbrotic cytokine production was investigated in
our study. Two particular molecular series were characterized,
including the pathways of miR-181c/uPA and miR-10a/PAI-1.
Those pathways are partially responsible for ﬁbroblast-mediated
collagen deposition. Our data suggest that miR-181c and miR-
10a play a role in the regulation of uPA as well as PAI-1 expres-
sion, respectively, in HFs, and changes in these two miRNAs con-
tribute to signiﬁcant alteration in Col1 secretion in HS.
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